VYUHPHARMA

Highlights from the Week of 30 June, 2025 - 07 July, 2025

UNICYCIVE THERAPEUTICS INC.

Unicycive Therapeutics receives a complete response letter for oxylanthanum carbonate to treat hyperphosphatemia in dialysis patients with chronic kidney disease

(FDA, CR)

Takeda

Takeda receives US FDA approval for GAMMAGARD LIQUID ERC, a ready-to-use low IgA therapy for primary immunodeficiency; the launch is planned for 2026, with the first-generation product to be discontinued

(FDA Approval)

AMGEN

Positive results from Amgen's Phase 3 trial showed that bemarituzumab plus chemotherapy significantly improves overall survival over chemotherapy alone in FGFR2b-positive gastric cancer

(Clinical trial, Results)

VYUHPHARMA

Highlights from the Week of 30 June, 2025 - 07 July, 2025

Dizal 迪哲

FDA grants accelerated approval to Dizal's ZEGFROVY, marking it as the exclusive oral targeted treatment for EGFR exon 20 insertion non-small cell lung cancer

(FDA Approval)

hikma.

FDA approves Hikma's TYZAVANTM, a ready-to-infuse vancomycin for conditions like skin and bone infections and lower respiratory tract infections

(FDA Approval)

Biocon Biologics
Transforming Healthcare. Transforming Lives.

European Commission approves Biocon Biologics' VEVZUO for preventing bone complications in advanced cancer and EVFRAXY for treating osteoporosis

(Biosimilars, EC Approval)

Highlights from the Week of 30 June, 2025 - 07 July, 2025

Neurizon enters into a global license agreement with Elanco to accelerate the commercialization of NUZ-001, an investigational therapy for neurodegenerative diseases like ALS

(Commercialization, Partnership)

Jazz Pharmaceuticals' ZIIHERA (zanidatamab) receives European Commission approval as the EU's first HER2-targeted therapy for advanced HER2-positive biliary tract cancer

(EU Approval)